Skip to content

The Use of Virtual Reality for the Treatment of Visual Vertigo.

The Use of Virtual Reality for the Treatment of Visual Vertigo.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03020654
Enrollment
18
Registered
2017-01-13
Start date
2017-01-31
Completion date
Unknown
Last updated
2018-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of Visual Vertigo

Brief summary

This study investigates the use of virtual environments presented on a head mounted display for the rehabilitation of those suffering with visual vertigo. The control group and treatment groups will be presented with two different sets of environments and be given the same head and eye exercises to complete within the environment. They will also be provided with at home exercises to complete.

Detailed description

Visual vertigo occurs after the balance system suffers damage (e.g after a viral infection such as labyrinthitis). This causes an over-reliance on the eyes to maintain balance which causes disorientation in busy environments such as the supermarket. The treatment involves trying to desensitise the individual to visually stimulating situations. Further head and eye exercises are completed alongside the exposure to overcome the damage done to the balance system.

Interventions

OTHERVirtual environment with fast moving objects

A beach/park environment with graded moving objects, the individual will complete head and eye exercises.

OTHERVirtual environment with no movement

A beach/park environment with static objects, the individual will complete head and eye exercises.

Sponsors

University of Manchester
CollaboratorOTHER
Sheffield Teaching Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Those who have been diagnosed with visual vertigo and have scored a significant level on the Situational Characteristic Questionnaire (over 0.74 as per Pavlou et al., 2006).

Exclusion criteria

* Those with or under investigation for epilepsy. * Those who have been determined to have no or limited balance function in both ears. * Those with reduced visual acuity that will leave them unable to view the 3D effects of the head mounted display. * Those with severe mental health disorders e.g. psychosis, paranoid disorders, bipolar disorder or a history of substance abuse. * Severe neck pain/ restricted movement. * Previous treatment for visual vertigo. * Those with an fluctuating vestibular disorder such as Ménière's disease or vestibular migraine. * Those with untreated Benign Paroxymal Positional Vertigo (BPPV). * Those with a significant brain injury, or head injury that results in a central vestibular disorder. * Those with an arrhythmia.

Design outcomes

Primary

MeasureTime frameDescription
Change in scoring on the Situational Characteristic QuestionnaireWeek 1 and Week 6A measure of visual vertigo symptom level

Secondary

MeasureTime frameDescription
Change in scoring on the PHQ-9 Questionnaire from week one to sixWeek 1 and Week 6A measure of depression symptom level
Change in scoring on the GAD-7 Questionnaire from week one to sixWeek 1 and Week 6A measure of anxiety symptom level

Other

MeasureTime frameDescription
Subjective questionnaireWeek 6A likert scale based questionnaire assessing acceptability of treatment
Change in head tracking observed at each weekly session for six weeks through numerical data extracted from the headset to show displacement of the head in the x, y and z planes of movement.Week 1, 2, 3, 4, 5 and 6Analysis of the head movement within each environment each week to see if there is any improvement

Countries

United Kingdom

Contacts

Primary ContactKirsty M Walker, BSc
kirsty.walker@sth.nhs.uk011427112131
Backup ContactPaul Bacon, PhD
paul.bacon@sth.nhs.uk01142712145

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026